EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery and characterization of a specific inhibitor of serine-threonine kinase cyclin-dependent kinase-like 5 (CDKL5) demonstrates role in hippocampal CA1 physiology

Anna Castano, Margaux Silvestre iD, Carrow I Wells iD, Jennifer L Sanderson, Carla A Ferrer, Han Wee Ong, Yi Lang, William Richardson, Josie A Silvaroli, Frances M Bashore iD, Jeffery L Smith iD, Isabelle M Genereux und 7 weitere

eLife · 25.07.2023 · 12

DOI: 10.7554/elife.88206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, online erschienen am 25.07.2023. Verfasst von Anna Castano und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Colorado School of Medicine, Aurora, United States. Hauptthemen laut MEDLINE: Hippocampus, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NINDS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathological loss-of-function mutations in cyclin-dependent kinase-like 5 ( CDKL5 ) cause CDKL5 deficiency disorder (CDD), a rare and severe neurodevelopmental disorder associated with severe and medically refractory early-life epilepsy, motor, cognitive, visual, and autonomic disturbances in the absence of any structural brain pathology. Analysis of genetic variants in CDD has indicated that CDKL5 kinase function is central to disease pathology. CDKL5 encodes a serine-threonine kinase with significant homology to GSK3β, which has also been linked to synaptic function. Further, Cdkl5 knock-out rodents have increased GSK3β activity and often increased long-term potentiation (LTP). Thus, development of a specific CDKL5 inhibitor must be careful to exclude cross-talk with GSK3β activity. We synthesized and characterized specific, high-affinity inhibitors of CDKL5 that do not have detectable activity for GSK3β. These compounds are very soluble in water but blood–brain barrier penetration is low. In rat hippocampal brain slices, acute inhibition of CDKL5 selectively reduces postsynaptic function of AMPA-type glutamate receptors in a dose-dependent manner. Acute inhibition of CDKL5 reduces hippocampal LTP. These studies provide new tools and insights into the role of CDKL5 as a newly appreciated key kinase necessary for synaptic plasticity. Comparisons to rodent knock-out studies suggest that compensatory changes have limited the understanding of the roles of CDKL5 in synaptic physiology, plasticity, and human neuropathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HippocampusProtein Serine-Threonine KinasesEpileptic SyndromesGlycogen Synthase Kinase 3 betaSpasms, InfantileMice, KnockoutHumansMiceAnimalsCyclin-Dependent Kinases

Stichwörter der Autor:innen

CDKL5GSK3LTPhippocampusneuroscienceprotein kinaserat

Substanzen

Glycogen Synthase Kinase 3 betaProtein Serine-Threonine KinasesCyclin-Dependent KinasesCDKL5 protein, humanCDKL5 protein, mouse

Autor:innen und Institutionen

  • Department of Pharmacology, University of Colorado School of Medicine, Aurora, United States.
  • Kinases and Brain Development Laboratory, The Francis Crick Institute, London, United Kingdom.
  • Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States.
  • Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, United States.
  • Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States.

ORCID-Profile: Margaux Silvestre, Carrow I Wells, Frances M Bashore, Jeffery L Smith, Kelvin Dempster, Navlot S Pabla, Tim A Benke, Sila K Ultanir

Förderung

  • Medical Research Council
  • NINDS NIH HHS
  • NIH HHS
  • Wellcome Trust
  • Cancer Research UK
  • NCATS NIH HHS
  • NIDDK NIH HHS
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Castano, A., Silvestre, M., Wells, C. I., Sanderson, J. L., Ferrer, C. A., Ong, H. W., Lang, Y., Richardson, W., Silvaroli, J. A., Bashore, F. M., Smith, J. L., Genereux, I. M., Dempster, K., Drewry, D. H., Pabla, N. S., Bullock, A. N., Benke, T. A., Ultanir, S. K., & Axtman, A. D. (2023). Discovery and characterization of a specific inhibitor of serine-threonine kinase cyclin-dependent kinase-like 5 (CDKL5) demonstrates role in hippocampal CA1 physiology. eLife, 12. https://doi.org/10.7554/elife.88206

Vancouver

Castano A, Silvestre M, Wells CI, Sanderson JL, Ferrer CA, Ong HW, et al. Discovery and characterization of a specific inhibitor of serine-threonine kinase cyclin-dependent kinase-like 5 (CDKL5) demonstrates role in hippocampal CA1 physiology. eLife. 2023;12. doi:10.7554/elife.88206

BibTeX
@article{Castano2023,
  author = {Castano, Anna and Silvestre, Margaux and Wells, Carrow I and Sanderson, Jennifer L and Ferrer, Carla A and Ong, Han Wee and Lang, Yi and Richardson, William and Silvaroli, Josie A and Bashore, Frances M and Smith, Jeffery L and Genereux, Isabelle M and Dempster, Kelvin and Drewry, David H and Pabla, Navlot S and Bullock, Alex N and Benke, Tim A and Ultanir, Sila K and Axtman, Alison D},
  title = {Discovery and characterization of a specific inhibitor of serine-threonine kinase cyclin-dependent kinase-like 5 (CDKL5) demonstrates role in hippocampal CA1 physiology},
  journal = {eLife},
  year = {2023},
  volume = {12},
  doi = {10.7554/elife.88206}
}
Kostenlos starten →